For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Coronary artery disease (CAD) is a global public health and socioeconomic problem that affects millions of lives each year. Percutaneous coronary interventions (PCIs) such as stenting and angioplasty have been widely adopted worldwide to treat a range of CAD indications. The market for devices used in PCI is a dynamic and competitive one that is saturated with numerous players trying to gain share by developing innovative technologies.
With the recent introduction and rapidly increasing adoption of innovative technologies such as DEB and BAS, an assessment of the impact of these technologies on the CAD management market is needed. Moreover, more clinical data from randomized clinical trials (RCTs) is now emerging that compares the safety and efficacy of these devices compared to conventional interventional treatment options, and which sheds additional light on the future of CAD management.
Global market for percutaneous coronary interventions, including coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloons, PTCA drug-eluting balloons (DEB), carotid stents, and renal stents, was valued at approximately $6.3 Billion in 2015. The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.5% to reach a valuation of $8.1 Billion in 2022.
Emerging stent technologies in the coronary stent market, including bioabsorbable stents (BASes) and the third generation of DESes with biodegradable polymer/polymer-free coatings, aim to address these unmet needs. The third generation of DESes has been developed to eliminate concerns associated with the permanent polymer coating, which is a cause of late and very late stent thrombosis. Drug-eluting BASes represent the fourth generation in the evolution of DES technology. Given that the stent scaffold degrades over a period of time, BASes offer several benefits, including a reduced risk of restenosis, avoiding the implantation of multiple layers of metal inside the vessel, improving the feasibility of future interventions, and enabling for late lumen gain.
Companies such as B. Braun, Biosensors International, Biotronik, and Terumo are key competitors to these large corporations, as they develop innovative coronary stent platforms. As the next generation of DESes and BASes enter the market, the current key players will need to retain and acquire market share by improving the clinical performance of their existing products. In addition, they will need to expand into or increase their presence in the emerging markets in order to take revenue away from their competitors in the future.
The report “MediPoint: Percutaneous Coronary Interventions - Global Analysis and Market Forecasts” focuses on the market outlook for PCI devices in the 39 major markets (39MM): Canada, Mexico, US, Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, Turkey, UK, Australia, China, India, Japan, New Zealand, South Korea, Taiwan, Argentina, Brazil, Chile, Egypt, Israel, Saudi Arabia, South Africa, and United Arab Emirates.
Specifically, this report provides the following:
• Overview of percutaneous coronary interventions, including reimbursement trends and M&A analysis
• Annualized total market revenue by type of device, procedure trends, and market outlooks by country through 2022.
• Comprehensive data split across different stages of development and analysis of emerging trends in design.
• Analysis of the current and future market competition in the global percutaneous coronary interventions market. Insightful review of the key industry drivers, opportunities, barriers and challenges.
Companies mentioned in this report: Aachen Resonance, Abbott Vascular, Alvimedica, amg International, B. Braun, Balton , Biosensors International, Biotronik, Blue Medical, Boston Specific, Cardionovum, Concept Medical, Disa Vascular, Elixir Medical, Eucatech, Eurocor, Hexacath, InSitu Technologies, Iramed, ITGI Medical, JW Medical Systems, Kyoto Medical Planning, Lepu Medical Technology, Medinol, Medtronic ,Meril Life Sciences, Micell Technologies, MicroPort, Minvasys, MIV Therapeutics, OrbusNeich, Relisys , Rontis Medical, Sahajanand Medical Technologies, Stentys, Svelte Medical Systems, Terumo, Translumina, Tryton Medical, Vascular Concepts.